Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine.
Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis discovers, develops and commercialises new medicines for a range of skin disorders, - an area of significant unmet medical need and high commercial potential. Creabilis has an exceptional track record in dermatological research and has used this experience to generate a rich pipeline of clinical and pre-clinical drug candidates that the company will market directly or in partnership. The most advanced product is CT327 for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes a number of pre-clinical drug candidates arising from its ground breaking drug discovery programmes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.